BRIDGEWATER, N.J., Sept. 16, 2020 /PRNewswire/ -- Insmed
Incorporated (Nasdaq: INSM), a global biopharmaceutical
company on a mission to transform the lives of patients with
serious and rare diseases, today announced that it will host an
R&D Day on Wednesday, September 30, 2020. The event is
scheduled to take place from 10:00 a.m. to 12:30 p.m.
ET in a virtual format.
The agenda will include an overview of recent developments for
the Company's pipeline candidates treprostinil palmitil and
brensocatib, as well as label expansion efforts and global
advancement updates for
ARIKAYCE® (amikacin liposome
inhalation suspension).
The program will also feature a presentation by Ronald J. Oudiz, M.D., FACP, FACC, FCCP. Dr.
Oudiz is a Professor of Medicine at the David Geffen School of
Medicine at UCLA, the Interim Chief,
Division of Cardiology, and a Director at the Liu Center for
Pulmonary Hypertension Lundquist Institute for Biomedical
Innovation at Harbor-UCLA Medical Center.
The call and accompanying slides will be webcast live on the
company's website at https://investor.insmed.com/events. To
listen to the conference call live, please dial (888)
317-6003 (domestic) or (412)
317-6061 (international) and reference conference ID
number 0587949.
A replay of the conference call will be accessible approximately
one hour after its completion through October 14, 2020 by dialing (877) 344-7529
(domestic) or (412) 317-0088 (international) and referencing replay
access code 10147009. A webcast of the call will also be archived
for 90 days under the Investor Relations section of the company's
website at https://investor.insmed.com/events.
About Insmed
Insmed Incorporated is a global biopharmaceutical company on a
mission to transform the lives of patients with serious and rare
diseases. Insmed's first commercial product, ARIKAYCE®
(amikacin liposome inhalation suspension), is the first and only
therapy approved in the United States for the treatment
of refractory Mycobacterium avium complex (MAC)
lung disease as part of a combination antibacterial drug regimen
for adult patients with limited or no alternative treatment
options. MAC lung disease is a chronic, debilitating condition that
can cause severe and permanent lung damage. Insmed is also
advancing brensocatib, a novel oral reversible inhibitor of
dipeptidyl peptidase 1 with therapeutic potential in bronchiectasis
and other inflammatory diseases, and treprostinil palmitil, an
inhaled formulation of a treprostinil prodrug that may offer a
differentiated product profile for rare pulmonary disorders,
including pulmonary arterial hypertension. For more information,
visit www.insmed.com.
Contact:
Investors:
Argot Partners
Laura Perry or Heather Savelle
(212) 600-1902
insmed@argotpartners.com
Media:
Mandy Fahey
Senior Director, Corporate Communications
Insmed
(732) 718-3621
amanda.fahey@insmed.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/insmed-to-host-rd-day-on-september-30-2020-301131791.html
SOURCE Insmed Incorporated